"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 15 | 3 | 18 |
| 1992 | 8 | 9 | 17 |
| 1993 | 9 | 12 | 21 |
| 1994 | 9 | 11 | 20 |
| 1995 | 25 | 17 | 42 |
| 1996 | 68 | 45 | 113 |
| 1997 | 58 | 39 | 97 |
| 1998 | 82 | 45 | 127 |
| 1999 | 72 | 47 | 119 |
| 2000 | 74 | 68 | 142 |
| 2001 | 81 | 65 | 146 |
| 2002 | 302 | 218 | 520 |
| 2003 | 351 | 266 | 617 |
| 2004 | 405 | 330 | 735 |
| 2005 | 517 | 377 | 894 |
| 2006 | 469 | 353 | 822 |
| 2007 | 507 | 417 | 924 |
| 2008 | 528 | 426 | 954 |
| 2009 | 556 | 556 | 1112 |
| 2010 | 629 | 528 | 1157 |
| 2011 | 586 | 567 | 1153 |
| 2012 | 600 | 565 | 1165 |
| 2013 | 662 | 574 | 1236 |
| 2014 | 730 | 588 | 1318 |
| 2015 | 651 | 578 | 1229 |
| 2016 | 650 | 579 | 1229 |
| 2017 | 649 | 529 | 1178 |
| 2018 | 552 | 493 | 1045 |
| 2019 | 227 | 188 | 415 |
| 2020 | 196 | 186 | 382 |
| 2021 | 56 | 86 | 142 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Anterior Scleritis Manifesting After Coronavirus Disease 2019: A Report of Two Cases. Cornea. 2021 Sep 01; 40(9):1204-1206.
-
Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept. Transplantation. 2021 09 01; 105(9):2119-2123.
-
Dermatology practice in the times of the COVID-19 pandemic. Indian J Dermatol Venereol Leprol. 2021 Sep-Oct; 87(5):603-610.
-
Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients. Transplantation. 2021 09 01; 105(9):e99.
-
Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. Transplantation. 2021 09 01; 105(9):e94-e95.
-
[Anti-SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases. Recommendations of the Italian Society on Nephrology's Working Group on Renal Immunopathology (Vaccine Task Force)]. G Ital Nefrol. 2021 Aug 30; 38(4).
-
COVID-19 and the Use of Immunomodulatory Agents in Ophthalmology Turk J Ophthalmol. 2021 08 27; 51(4):231-242.
-
Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders. Neurol Neuroimmunol Neuroinflamm. 2021 11; 8(6).
-
The impact of the COVID-19 pandemic on microbial keratitis presentation patterns. PLoS One. 2021; 16(8):e0256240.
-
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study. J Neuroimmunol. 2021 10 15; 359:577696.